Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

56.88USD
11:02pm IST
Change (% chg)

$0.25 (+0.44%)
Prev Close
$56.63
Open
$56.58
Day's High
$56.91
Day's Low
$56.29
Volume
304,621
Avg. Vol
2,060,055
52-wk High
$70.04
52-wk Low
$49.97

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Says Opdivo + Yervoy Now Approved In 3 Tumor Types
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) + LOW-DOSE YERVOY® (IPILIMUMAB) IS THE FIRST IMMUNO-ONCOLOGY COMBINATION APPROVED FOR MSI-H/DMMR MCRC PATIENTS WHO PROGRESSED FOLLOWING TREATMENT WITH A FLUOROPYRIMIDINE, OXALIPLATIN AND....BRISTOL-MYERS SQUIBB CO - IN CHECKMATE -142 TRIAL, OPDIVO + YERVOY DEMONSTRATED AN OVERALL RESPONSE RATE OF 46%.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS NOW APPROVED IN THREE TUMOR TYPES, DOSING AND ADMINISTRATION VARIES BY TUMOR.BRISTOL-MYERS SQUIBB CO - OPDIVO + YERVOY IS ASSOCIATED WITH WARNINGS AND PRECAUTIONS SUCH AS IMMUNE-MEDIATED PNEUMONITIS, COLITIS, HEPATITIS.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS ALSO ASSOCIATED WITH WARNINGS & PRECAUTIONS LIKE ENDOCRINOPATHIES, NEPHRITIS & RENAL DYSFUNCTION, SKIN ADVERSE REACTIONS.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS ALSO ASSOCIATED WITH WARNINGS & PRECAUTIONS LIKE ENCEPHALITIS, OTHER ADVERSE REACTIONS; INFUSION REACTIONS.BRISTOL-MYERS SQUIBB CO - YERVOY CAN RESULT IN SEVERE AND FATAL IMMUNE-MEDIATED ADVERSE REACTIONS.  Full Article

Exalenz Bioscience's Non-Invasive Breathid Test To Be Evaluated In Two Bristol-Myers Squibb Phase 2B Clinical Trials In Adult Patients With Nash
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Exalenz Bioscience Ltd ::EXALENZ BIOSCIENCE’S NON-INVASIVE BREATHID® TEST TO BE EVALUATED IN TWO BRISTOL-MYERS SQUIBB PHASE 2B CLINICAL TRIALS IN ADULT PATIENTS WITH NASH.EXALENZ BIOSCIENCE LTD - BREATHID (13)C-METHACETIN BREATH TEST WILL BE EVALUATED IN TWO PHASE 2B CLINICAL STUDIES SPONSORED BY BRISTOL-MYERS SQUIBB.  Full Article

European Commission Approves Expanded Indication For Sprycel
Thursday, 5 Jul 2018 

July 5 (Reuters) - Bristol-Myers Squibb Co ::EUROPEAN COMMISSION APPROVES EXPANDED INDICATION FOR SPRYCEL (DASATINIB) TO INCLUDE TREATMENT OF CHILDREN WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE.BRISTOL-MYERS SQUIBB CO - EC APPROVAL IS BASED ON DATA FROM CA180-226 TRIAL.  Full Article

Bristol-Myers Says FDA Accepts Application For Opdivo Plus Low-Dose Yervoy
Friday, 22 Jun 2018 

June 21 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS APPLICATION FOR OPDIVO PLUS LOW-DOSE YERVOY FOR TREATMENT OF FIRST-LINE NON-SMALL CELL LUNG CANCER IN PATIENTS WITH TUMOR MUTATIONAL BURDEN ≥10 MUT/MB.BRISTOL-MYERS SQUIBB CO - TARGET FDA ACTION DATE IS FEBRUARY 20, 2019.BRISTOL-MYERS SQUIBB CO - SUBMISSION BASED ON POSITIVE RESULTS FROM PART 1 OF PHASE 3 STUDY CHECKMATE -227.  Full Article

Bristol-Myers Squibb Announces Dividend
Friday, 15 Jun 2018 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION.  Full Article

Bristol-Myers Says Patients In Opdivo Plus Low-Dose Yervoy Trial Reported Fewer Kidney Cancer Symptoms
Friday, 1 Jun 2018 

June 1 (Reuters) - Bristol-Myers Squibb Co ::OPDIVO (NIVOLUMAB) PLUS LOW-DOSE (1MG/KG) YERVOY (IPILIMUMAB) PROVIDED SIGNIFICANT AND SUSTAINED HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN CHECKMATE -214 STUDY.BRISTOL-MYERS SQUIBB - PATIENTS IN OPDIVO PLUS LOW-DOSE YERVOY ARM REPORTED FEWER KIDNEY CANCER SYMPTOMS AS MEASURED BY NCCN FKSI-19.BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, TREATMENT WITH OPDIVO PLUS LOW-DOSE YERVOY LED TO STATISTICALLY SIGNIFICANT DIFFERENCES.BRISTOL-MYERS SQUIBB - PATIENTS IN STUDY TREATED WITH OPDIVO PLUS LOW-DOSE YERVOY REPORTED SIGNIFICANT BENEFITS IN DISEASE-RELATED SYMPTOMS.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Trial Collaboration And Supply Agreement With Bristol-Myers Squibb
Thursday, 24 May 2018 

May 24 (Reuters) - Bristol-Myers Squibb Co ::IDERA PHARMACEUTICALS SAYS EFFECTIVE MAY 18, 2018 ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL-MYERS SQUIBB.IDERA PHARMACEUTICALS - DEAL TO CLINICALLY EVALUATE COMBINATION OF CO'S TLR-9 AGONIST IMO-2125 WITH BMS'S THERAPY YERVOY.IDERA PHARMACEUTICALS INC - BMS GRANTED CO NON-EXCLUSIVE, NON-TRANSFERRABLE, ROYALTY-FREE LICENSE UNDER INTELLECTUAL PROPERTY TO USE YERVOY IN TRIAL.IDERA PHARMACEUTICALS - WILL SPONSOR, FUND, CONDUCT CO'S OPEN-LABEL, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH YERVOY.IDERA PHARMACEUTICALS INC - UPON TERMINATION OF DEAL, LICENSES GRANTED TO CO TO USE YERVOY(REG) IN TRIAL WILL TERMINATE.  Full Article

Advantagene Announces Clinical Trial Collaboration
Friday, 27 Apr 2018 

April 27 (Reuters) - Bristol-Myers Squibb Co ::ADVANTAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION.ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB.ADVANTAGENE - COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO'S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL'S OPDIVO.ADVANTAGENE - ITS INVESTIGATIONAL GMCI COMBINED WITH OPDIVO IS TO TREAT NEWLY DIAGNOSED MALIGNANT GLIOMA PATIENTS GETTING SURGERY WITH/WITHOUT TEMOZOLOMIDE.  Full Article

CEO Says Bristol-Myers Still A Growth Company
Thursday, 26 Apr 2018 

April 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB SEES CONTINUED GROWTH IN ANTICOAGULANT MARKET SHARE FOR ELIQUIS.BRISTOL-MYERS CEO SAYS CONTINUES TO SEE BMS AS A GROWTH COMPANY AND OPDIVO AS A GROWTH FRANCHISE.  Full Article

Bristol-Myers Squibb Reports Q1 GAAP Earnings Per Share $0.91
Thursday, 26 Apr 2018 

April 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.94.Q1 GAAP EARNINGS PER SHARE $0.91.Q1 REVENUE $5.2 BILLION VERSUS I/B/E/S VIEW $5.23 BILLION.Q1 EARNINGS PER SHARE VIEW $0.85 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GAAP EARNINGS PER SHARE $2.70 TO $2.80.QTRLY SPRYCEL WORLDWIDE REVENUE $438 MILLION VERSUS $463 MILLION REPORTED LAST YEAR.QTRLY OPDIVO WORLDWIDE REVENUE $1,511 MILLION VERSUS $1,127 MILLION REPORTED LAST YEAR.INCREASING 2018 NON-GAAP EPS GUIDANCE RANGE FROM $3.15 - $3.30 TO $3.35 - $3.45.QTRLY ELIQUIS WORLDWIDE REVENUE $1,506 MILLION VERSUS $1,101 MILLION REPORTED LAST YEAR.QTRLY YERVOY WORLDWIDE REVENUE $249 MILLION VERSUS $330 MILLION REPORTED LAST YEAR.SEES 2018 WORLDWIDE REVENUES INCREASING IN MID-SINGLE DIGITS.U.S. REVENUES INCREASED 1% TO $2.8 BILLION IN THE QUARTER COMPARED TO THE SAME PERIOD A YEAR AGO.QTRLY INTERNATIONAL REVENUES INCREASED 10%.  Full Article

Italy - Factors to watch on July 6

The following factors could affect Italian markets on Friday.